PHAT

SEC source: 0001209191-22-004492 · doc4.xml · nonDerivative · entry 1

Guzzo Anthony J. · CIK 0001432098 · VP, Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,399

F1 · shares: Represents restricted stock units ("RSUs") granted on January 19, 2022. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2022, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

F2 · balance_after: Includes 2,399 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2021 and January 2022.

SEC source: 0001209191-22-004496 · doc4.xml · derivative · entry 4

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 97,500

Underlying: Common Stock · 97,500 shares

Expires 2032-01-18

F3 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on January 19, 2023, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.

SEC source: 0001209191-22-004496 · doc4.xml · nonDerivative · entry 1

Nabulsi Azmi · CIK 0001791412 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,378

F1 · shares: Represents restricted stock units ("RSUs") granted on January 19, 2022. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2022, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

F2 · balance_after: Includes 1,425 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2021 and January 2022 and 453 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan which were inadvertenly omitted from the most recent Form 4.

SEC source: 0001395064-21-000231 · wf-form4_163636942764423.xml · derivative · entry 4

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,359,304

Underlying: Common Stock · 228,696 shares

Expires 2029-05-07

F1 · derivative.exercise_price: On November 4, 2021, the Reporting Person exercised a Warrant to purchase 228,696 shares of the Issuers common stock with an exercise price of $0.00004613 per share. The Reporting Person paid the exercise price on a cashless basis in accordance with the terms of such Warrants, resulting in the Issuer withholding a number of shares (or portion thereof) to satisfy the exercise price and issuing to the Reporting Person the remaining number of shares. The Issuer also paid the Reporting Person $8.45 in lieu of a fractional share.

F1 · shares: On November 4, 2021, the Reporting Person exercised a Warrant to purchase 228,696 shares of the Issuers common stock with an exercise price of $0.00004613 per share. The Reporting Person paid the exercise price on a cashless basis in accordance with the terms of such Warrants, resulting in the Issuer withholding a number of shares (or portion thereof) to satisfy the exercise price and issuing to the Reporting Person the remaining number of shares. The Issuer also paid the Reporting Person $8.45 in lieu of a fractional share.

SEC source: 0001395064-21-000231 · wf-form4_163636942764423.xml · nonDerivative · entry 3

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

SEC source: 0001395064-21-000231 · wf-form4_163636942764423.xml · nonDerivative · entry 2

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,100,000

F1 · shares: On November 4, 2021, the Reporting Person exercised a Warrant to purchase 228,696 shares of the Issuers common stock with an exercise price of $0.00004613 per share. The Reporting Person paid the exercise price on a cashless basis in accordance with the terms of such Warrants, resulting in the Issuer withholding a number of shares (or portion thereof) to satisfy the exercise price and issuing to the Reporting Person the remaining number of shares. The Issuer also paid the Reporting Person $8.45 in lieu of a fractional share.

SEC source: 0001395064-21-000231 · wf-form4_163636942764423.xml · nonDerivative · entry 1

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,100,001

F1 · shares: On November 4, 2021, the Reporting Person exercised a Warrant to purchase 228,696 shares of the Issuers common stock with an exercise price of $0.00004613 per share. The Reporting Person paid the exercise price on a cashless basis in accordance with the terms of such Warrants, resulting in the Issuer withholding a number of shares (or portion thereof) to satisfy the exercise price and issuing to the Reporting Person the remaining number of shares. The Issuer also paid the Reporting Person $8.45 in lieu of a fractional share.

F1 · price: On November 4, 2021, the Reporting Person exercised a Warrant to purchase 228,696 shares of the Issuers common stock with an exercise price of $0.00004613 per share. The Reporting Person paid the exercise price on a cashless basis in accordance with the terms of such Warrants, resulting in the Issuer withholding a number of shares (or portion thereof) to satisfy the exercise price and issuing to the Reporting Person the remaining number of shares. The Issuer also paid the Reporting Person $8.45 in lieu of a fractional share.

SEC source: 0001209191-21-060109 · doc4.xml · nonDerivative · entry 2

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,211,346

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.82 to $32.58. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-060109 · doc4.xml · nonDerivative · entry 1

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,213,875

F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.17 to $33.16. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-057517 · doc4.xml · nonDerivative · entry 3

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,229,346

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.66 to $32.57. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-057517 · doc4.xml · nonDerivative · entry 2

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,233,446

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.23 to $33.36. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-057517 · doc4.xml · nonDerivative · entry 1

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,233,770

F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.20 to $33.1650. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-052287 · doc4.xml · nonDerivative · entry 2

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,247,346

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.80.The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-052287 · doc4.xml · nonDerivative · entry 1

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,261,137

F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.98. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · balance_after: The total number of outstanding shares reflects an increase of 4,401 shares to correct an arithmetic error in the total number of shares initially reported on his Form 4 filed on November 9, 2020.

SEC source: 0001209191-21-046678 · doc4.xml · derivative · entry 1

Parikh Asit · CIK 0001796787 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,500

Underlying: Common Stock · 7,500 shares

Expires 2031-07-12

F1 · derivative.exercise_date: The option was granted as compensation for services provided to the Registrant as a director. The option shall vest and/or become exercisable on the first anniversary of the date of grant subject to Reporting Person's continuing in service on the Board through such vesting date.

SEC source: 0001395064-21-000153 · wf-form4_162582536885803.xml · nonDerivative · entry 1

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 871,305

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.26. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000148 · wf-form4_162556619453955.xml · nonDerivative · entry 2

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 873,914

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

SEC source: 0001395064-21-000148 · wf-form4_162556619453955.xml · nonDerivative · entry 1

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 874,014

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.50. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001209191-21-043851 · doc4.xml · nonDerivative · entry 3

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,260,945

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.85 to $34.77. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-043851 · doc4.xml · nonDerivative · entry 2

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,274,905

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.86 to $35.21. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-21-043851 · doc4.xml · nonDerivative · entry 1

Socks David A · CIK 0001378847 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · David A. Socks 2013 Revocable Trust

Disclosed balance after: 1,275,061

F1 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.85 to $34.83. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001395064-21-000142 · wf-form4_162496343440654.xml · nonDerivative · entry 3

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 882,240

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F4 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.21. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000142 · wf-form4_162496343440654.xml · nonDerivative · entry 2

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 882,610

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F3 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $36.00 to $36.16. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000142 · wf-form4_162496343440654.xml · nonDerivative · entry 1

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 883,860

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.97. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000125 · wf-form4_162462041149796.xml · nonDerivative · entry 2

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 906,741

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.50. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000125 · wf-form4_162462041149796.xml · nonDerivative · entry 1

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 917,589

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

SEC source: 0001395064-21-000121 · wf-form4_162444332161973.xml · nonDerivative · entry 2

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 917,789

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

SEC source: 0001395064-21-000121 · wf-form4_162444332161973.xml · nonDerivative · entry 1

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 917,889

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.87. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000119 · wf-form4_162427022767333.xml · nonDerivative · entry 2

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 927,183

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F3 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.29. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000119 · wf-form4_162427022767333.xml · nonDerivative · entry 1

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 932,581

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.35. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000113 · wf-form4_162383795840024.xml · nonDerivative · entry 1

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 935,886

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.40. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000111 · wf-form4_162340613411314.xml · nonDerivative · entry 2

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 938,712

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F3 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.43. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000111 · wf-form4_162340613411314.xml · nonDerivative · entry 1

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 940,814

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.53. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000109 · wf-form4_162323525319328.xml · nonDerivative · entry 2

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 942,005

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

SEC source: 0001395064-21-000109 · wf-form4_162323525319328.xml · nonDerivative · entry 1

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 942,105

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.30. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000107 · wf-form4_162280219725418.xml · nonDerivative · entry 1

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 944,369

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.04 to $35.87. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000105 · wf-form4_162262847834335.xml · nonDerivative · entry 5

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 948,669

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F6 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $36.00 to $36.55. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000105 · wf-form4_162262847834335.xml · nonDerivative · entry 4

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 952,636

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F5 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.01 to $35.99. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000105 · wf-form4_162262847834335.xml · nonDerivative · entry 3

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 959,880

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F4 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $37.00 to $37.99. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000105 · wf-form4_162262847834335.xml · nonDerivative · entry 2

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 961,984

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F3 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $36.00 to $36.96. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000105 · wf-form4_162262847834335.xml · nonDerivative · entry 1

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 964,652

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.99. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000103 · wf-form4_162219666011290.xml · nonDerivative · entry 4

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 968,785

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F5 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $37.34 to $37.92. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000103 · wf-form4_162219666011290.xml · nonDerivative · entry 3

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 971,064

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F4 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $36.35 to $37.33. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000103 · wf-form4_162219666011290.xml · nonDerivative · entry 2

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 977,238

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F3 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $36.72 to $37.22. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000103 · wf-form4_162219666011290.xml · nonDerivative · entry 1

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 982,127

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.71 to $36.70. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000089 · wf-form4_162203653751929.xml · nonDerivative · entry 4

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 989,596

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F5 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $36.50 to $36.72. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000089 · wf-form4_162203653751929.xml · nonDerivative · entry 3

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 990,144

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F4 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.62 to $36.46. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000089 · wf-form4_162203653751929.xml · nonDerivative · entry 2

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000,543

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F3 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $36.00 to $36.33. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001395064-21-000089 · wf-form4_162203653751929.xml · nonDerivative · entry 1

TAKEDA PHARMACEUTICAL CO LTD · CIK 0001395064 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,002,226

F1 · kind: The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 2, 2021.

F2 · price: Reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $35.01 to $35.99. Information regarding the number of shares sold at each separate price will be provided upon request by the Staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer.

SEC source: 0001209191-21-035482 · doc4.xml · derivative · entry 1

FIELDS HEIDI · CIK 0001014330 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2031-05-20

F1 · derivative.exercise_date: The option was granted pursuant to the Registrant's Non-Employee Director Compensation Program. The option shall vest and/or become exercisable on the first to occur of (A) the first anniversary of the date of grant or (B) the next occurring annual meeting of the Registrant's stockholders, subject to Reporting Person's continuing in service on the Board through such vesting date.